These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22131881)

  • 1. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
    Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
    Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
    Kirabo A; Embury J; Kiss R; Polgár T; Gali M; Majumder A; Bisht KS; Cogle CR; Keseru GM; Sayeski PP
    J Biol Chem; 2011 Feb; 286(6):4280-91. PubMed ID: 21127060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
    Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
    J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
    Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
    Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
    Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
    Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.
    Majumder A; Magis AT; Park SO; Figueroa NC; Baskin R; Kirabo A; Allan RW; Zhao ZJ; Bisht KS; Keseru GM; Sayeski PP
    Exp Hematol; 2012 Jan; 40(1):22-34. PubMed ID: 22019628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
    Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
    Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
    Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
    Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
    Bhagwat N; Koppikar P; Keller M; Marubayashi S; Shank K; Rampal R; Qi J; Kleppe M; Patel HJ; Shah SK; Taldone T; Bradner JE; Chiosis G; Levine RL
    Blood; 2014 Mar; 123(13):2075-83. PubMed ID: 24470592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
    Quintás-Cardama A
    Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
    Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
    Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
    Manshouri T; Estrov Z; Quintás-Cardama A; Burger J; Zhang Y; Livun A; Knez L; Harris D; Creighton CJ; Kantarjian HM; Verstovsek S
    Cancer Res; 2011 Jun; 71(11):3831-40. PubMed ID: 21512135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
    Tiedt R; Hao-Shen H; Sobas MA; Looser R; Dirnhofer S; Schwaller J; Skoda RC
    Blood; 2008 Apr; 111(8):3931-40. PubMed ID: 18160670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments.
    Majumder A; Kirabo A; Karrupiah K; Tsuda S; Caldwell-Busby J; Cardounel AJ; Keseru GM; Sayeski PP
    Biochemistry; 2011 Sep; 50(36):7774-86. PubMed ID: 21823612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.